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OBJECTIVE
To assess clinical outcomes and cost-effectiveness of using continuous positive
airway pressure (CPAP) to manage obstructive sleep apnea (OSA) in patients with
type 2 diabetes (T2D) from the perspective of the U.K.’s National Health Service
(NHS).
RESEARCH DESIGN AND METHODS
Using a case-control design, 150 CPAP-treated patients with OSA and T2D were
randomly selected from The Health Improvement Network (THIN) database (a
nationally representative database of patients registered with general practi-
tioners in the U.K.) and matched with 150 OSA and T2D patients from the same
database who were not treated with CPAP. The total NHS cost and outcomes of
patient management in both groups over 5 years and the cost-effectiveness of
CPAP compared with no CPAP treatment were estimated.
RESULTS
Using CPAP was associated with signiﬁcantly lower blood pressure at 5 years and
increasingly lower HbA1c levels over 5 consecutive years comparedwith untreated
OSA patients. At 5 years, the HbA1c level in the CPAP-treated group was 8.2%
(66.0 mmol/mol) vs. 12.1% (108.4 mmol/mol) in the control group (P < 0.03). Use
of CPAP signiﬁcantly increased patients’ health status by 0.27 quality-adjusted life
years (QALYs) per patient over 5 years (P < 0.001) and NHS management costs by
£4,141 per patient over 5 years; the cost per QALY gained with CPAP was £15,337.
CONCLUSIONS
Initiating treatment with CPAP in OSA patients with T2D leads to signiﬁcantly
lower blood pressure and better controlled diabetes and affords a cost-effective
use of NHS resources. These observations have the potential for treatment mod-
iﬁcation if conﬁrmed in a prospective study.
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Obstructive sleep apnea (OSA) and type 2
diabetes (T2D) are common conditions
that often coexist (1). Obesity is a risk
factor for both OSA and T2D (2,3); how-
ever, OSA has been reported to be asso-
ciated with increased insulin resistance
independently of obesity (4,5). Never-
theless, even just the coexistence of
OSA and T2D has important clinical,
public health, and economic implica-
tions. They are both independently
linked to high cardiovascular morbidity
and mortality (6–8), and both are po-
tential therapeutic targets for either
primary or secondary prevention of car-
diovascular disease. OSA is also linked to
drug-resistant hypertension (9). Chronic
sleep loss, a consequence of OSA, is also
associated with decreased glucose toler-
ance, decreased leptin, and an increase
in evening cortisol levels (10,11). Addi-
tionally, the daytime sleepiness experi-
enced by patients with OSA can lead to
road trafﬁc and occupational accidents
(12), as well as impact on their quality
of life (13).
The prevalence of moderate OSA in
patients with T2D has been reported
to be 49% of men and 21% of women
(14). This ﬁgure is set to rise as the prev-
alence of obesity and T2D in the popu-
lation increases (15).
Continuous positive airway pressure
(CPAP) is an effective treatment for
moderate-to-severe OSA sufferers (16)
and affords a cost-effective use of
health care resources to the U.K.’s Na-
tional Health Service (NHS) (17). The
short-term effect of CPAP treatment
on diabetes is controversial, with some
studies reporting an improvement in in-
sulin sensitivity (18–20) and a reduction
in HbA1c levels (21,22), while others
have reported no effect (23).
It is now impossible to perform an
ethical randomized controlled trial of
CPAP versus no treatment in patients
with OSA over a long period. Therefore,
comparing nonrandomly allocated pa-
tients, withmaximal attempts to control
for the inevitable baseline differences, is
the best study design that can be used.
The effect of CPAP treatment in OSA pa-
tients with T2D has been little studied in
the real clinical practice setting, espe-
cially over periods as long as 5 years.
Accordingly, the current study used
The Health Improvement Network
(THIN) database (a nationally represen-
tative database of patients registered
with general practitioners [GPs] in
the U.K.) (24) to examine the clinical
outcomes and cost-effectiveness of
using CPAP to manage OSA patients
with T2D in clinical practice in the
U.K. over 5 years from the perspective
of the NHS.
RESEARCH DESIGN AND METHODS
THIN Database
The THIN database (Cegedim, London,
U.K.) contains computerized informa-
tion on.9 million anonymized patients
entered by GPs from 500 practices
across the U.K. general practices across
the U.K. using Vision Practice Manage-
ment Software are invited to participate
in the database and are self-selecting.
The patient data within THIN have
been shown to be representative of
the U.K. population in terms of demo-
graphics and disease distribution (24).
Read codes are a coded thesaurus of
clinical terms that are used by clinicians
in the U.K. to record patient ﬁndings and
procedures in health and social care in-
formation technology systems (25).
They have been in use in the NHS since
1985 (25) and have been used to code
speciﬁc diagnoses in the THIN database.
A drug dictionary based on data from
the Multilex classiﬁcation has been
used to code drugs in the database. Suc-
cessive updates of patients’ records to
the database include any subsequent
changes made by GPs.
The computerized information in the
THIN database includes patients’ demo-
graphics, details from GP consultations,
specialist referrals, nurse and other cli-
nician visits, hospital admissions, diag-
nostic and therapeutic procedures,
laboratory tests, and prescriptions is-
sued by GPs that are directly generated
by the general practice’s information
technology system. Hence, the informa-
tion contained in the THIN database re-
ﬂects real clinical practice, as it is based
on actual patient records. Moreover,
GPs are the gatekeepers to health care
in the U.K., and patients’ entire medical
history is theoretically stored in their
primary care record.
Study Population
At the time of the study, the THIN data-
base contained 1,896 patients with OSA
and T2D. With use of data from our pre-
vious study in patients with OSA with-
out T2D (17), it was estimated that
CPAP-treated patients would have 3.9
QALYS at 5 years and untreated patients
would have 3.3 QALYs. Power calcula-
tions showed that a sample size of 150
patients in each group would be sufﬁ-
cient to detect this difference with 95%
power and a type 1 error of 0.05. Hence,
the study population comprised a ran-
dom sample of 150 patients from the
THIN database who were 18 years of
age or over, had a Read code for OSA
and T2D, and had at least 5 years’ follow-
up data in their case record (but not
necessarily for OSA) after the start of
treatment with CPAP unless they died.
The CPAP-treated patients were indi-
vidually matched with a randomly se-
lected cohort of 150 control patients
from the THIN database according to
age, sex, their general practice, date of
diagnosis of OSA and T2D, never having
received CPAP for the treatment of their
OSA, and having had at least 5 years’
follow-up data in their case record
(but not necessarily for OSA) after the
start date of CPAP in their matched
OSA-treated patient unless they died.
Ethics Approval
Ethics approval to use patients’ records
from the THIN database for this study
was obtained from the Research Ethics
Committee that appraises studies using
the THIN database.
Study Variables and Statistical
Analyses
Information was systematically ex-
tracted from the patients’ records over
the 5-year follow-up period according to
the protocol approved by the ethics
committee and included age, sex, BMI,
smoking status, HbA1c levels, blood
pressure, symptoms, morbidities, and
CPAP compliance. Patients’ Charlson
Comorbidity Index Score (CCIS) at base-
line was also calculated (26). The CCIS
encompasses 19 medical conditions
weighted 1–6, which were weighted ac-
cording to age, and these were used to
generate a total comorbidity score rang-
ing from 2 to 14. All information on
health care resource use, prescribed
medication, and clinical outcomes
over a period of 5 years from the start
of CPAP treatment, or the matched
date in the control patients, was also
extracted.
Patients’ outcomes and resource
use were quantiﬁed for both groups.
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Differences between the groups were
tested for statistical signiﬁcance using a
Mann-Whitney U test or x2 test and as-
sumed to be attributable to CPAP treat-
ment. Differences within each group
were tested for statistical signiﬁcance
using a Wilcoxon matched-pair signed-
rank test.
With use of ANCOVA, differences in
patients’ outcomes and resource use be-
tween treatments were adjusted for any
heterogeneity in the following covariates:
age, sex, baseline comorbidities, base-
line blood pressure, baseline BMI, smok-
ing status, and GP visits and hospital
admissions in the year before the study
start date. Logistic regression was used
to investigate relationships between
baseline variables and clinical out-
comes. Multiple linear regression was
also used to assess the impact of pa-
tients’ baseline variables on resource
use and clinical outcomes. All statisti-
cal analyses were performed using
IBM SPSS Statistics (version 21.0; IBM
Corporation).
Health Economic Modeling
A case-control model was constructed
and populated with health care re-
source utilization and clinical outcomes
extracted from the THIN data set.
The model spans a period of 5 years
from the start of CPAP treatment
or the matched date among control
patients.
Utility scores express patient prefer-
ences for speciﬁc health states on a
scale ranging from 0, representing
death, to 1, representing perfect health.
These scores provide the weights
to estimate health-related quality of
life (HRQoL) in terms of the number of
quality-adjusted life years (QALYs)
gained by an intervention or service.
HRQoL was not collected in the THIN
database. However, it has been re-
ported that the baseline HRQoL of indi-
viduals with treated and untreated OSA
are 7% and 16% lower than that for av-
erage people of the same age, respec-
tively (27). Hence, the baseline utility of
each patient in the THIN data set was
estimated to be 7% and 16% less than
that for average people of the same age
in the catalogue of EQ-5D scores for the
U.K. (28). Accordingly, the mean base-
line utility value was estimated to
be 0.747 and 0.676 in the CPAP-treated
and untreated group, respectively.
These values were consistent with val-
ues assigned to treated/untreated OSA
patients in other studies using EQ-5D
methodology (29,30). The baseline util-
ity value for each patient was then re-
duced by applying a decrement upon
the ﬁrst occurrence of each chronic con-
dition experienced by a patient during
the study period using the values re-
ported in the same catalogue of EQ-5D
scores (28). This enabled an estimation
of patients’ expected health status in
terms of the number of QALYs at 5 years
from the start of CPAP treatment or the
matched date among control patients.
Model Outputs
The primary measure of clinical outcome
was patients’ health status in terms of the
number of QALYs at ﬁve years. Secondary
measures were a range of outcomes that
included BMI and HbA1c levels.
By assignment of unit resource costs
at 2011/2012 prices (31–33) to the re-
source utilization estimates within
the model, the health care cost of
managing patients in each group over
5 years from the matched start dates
was estimated.
Cost-effectiveness Analyses
The cost-effectiveness of CPAP relative
to no treatment was calculated as the
difference between the expected costs
of CPAP-treated patients and control pa-
tients divided by the difference in the
number of QALYs between the two
groups and expressed as the cost per
QALY gained.
Sensitivity Analyses
For assessment of uncertainty, boot-
strapping was undertaken to estimate
the distribution of expected costs, out-
comes, and cost-effectiveness ratios.
This involved generating 10,000 subsets
of the data from each group on the basis
of random sampling and replacing the
data once sampled. Use of these sub-
sets enabled the construction of a
cost-effectiveness acceptability curve
showing the probability of CPAP treat-
ment being cost-effective at different
thresholds. Additionally, deterministic
sensitivity analyses were performed on
all of the model’s inputs to identify how
the incremental cost-effectiveness of
CPAP treatment would change by vary-
ing the different parameters in the
model.
RESULTS
Patients’ Characteristics
Patients in both groups were matched
by age, sex, and their general practice.
Additionally, there was no signiﬁcant
difference in the level of socioeconomic
deprivation (using the Townsend Depri-
vation Index) between the two groups.
With use of a x2 test, it was found that
there were no signiﬁcant differences be-
tween the groups in the percent of pa-
tients diagnosed with a comorbidity
prior to the study start date. However,
prior to the study start date, signiﬁ-
cantly more CPAP-treated patients
were obese and signiﬁcantly more con-
trol patients were smokers (Table 1).
Furthermore, 12% of CPAP-treated
patients and 17% of control patients
stopped smoking during the study pe-
riod at amean of 3.7 years after the study
start date, and ~80% of nonsmokers in
both groups at the study start date were
ex-smokers.
Patient Management and Outcomes
From the time of diagnosis of OSA, it
took a mean 19.6 6 31.2 months to
the start of CPAP treatment. Over the
5-year follow-up period, 139 patients re-
mained on CPAP treatment. Hence, ad-
herence ranged from 93% in year 1 to
89% in year 5. Additionally, objective
CPAP adherence data were available
for only 11 patients. Based on what
was written in the medical records of
these patients, CPAP adherence was a
mean of 5.8 6 1.0 h per night (range
4.0–7.2) for these 11 patients.
In both groups, patients’ blood pres-
sure declined over the study period.
Patients’ systolic pressure was not sig-
niﬁcantly lower than their baseline
value until year 3 (P = 0.001) in the
CPAP-treated group and year 4 in the
control group (P = 0.001). However, pa-
tients’ diastolic pressure in both groups
was signiﬁcantly lower than their base-
line value by year 2 (P, 0.01). Addition-
ally, patients’ blood pressure in the
CPAP-treated group was signiﬁcantly
lower than that of control patients by
year 5 (Table 2). Multiple regression
showed that patients’ blood pressure
was only affected by CPAP (P , 0.05)
and not by any other covariate.
Over the study period, more control
patients became obese, thus catching
up with the CPAP-treated group where
there were no changes in obesity.
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Hence, at 5 years there was no signiﬁ-
cant difference between the two groups
in terms of the percentage of obese pa-
tients (Table 2). However, CPAP-treated
patients had signiﬁcantly better con-
trolled diabetes than the control patients
(Fig. 1 and Table 2) and a signiﬁcantly
better HRQoL (Table 2). Two percent of
CPAP-treated patients, and 11% of con-
trol patients, had no diagnosed symp-
toms in the year before the study start
date. During the study period, signiﬁ-
cantly more CPAP-treated patients were
diagnosed with a cardiac arrhythmia, and
signiﬁcantly more control patients
were diagnosed with diabetic retinopa-
thy (Table 2). Additionally, 3% of CPAP-
treated patients and 3% of control
patients experienced no new symptoms
during the study period.
Logistic regression showed that sex
was an independent predictor of having
controlled diabetes. Female patients
were four times more likely than males
to have normal HbA1c levels at 5 years
(odds ratio 4.78; P, 0.02). Multiple re-
gression showed that patients’ HRQoL
over the ﬁve years was higher among
females (0.11 more QALYs among fe-
males than males [P , 0.03]).
Health Care Resource Use Associated
With Patient Management
Patients in both groups were predomi-
nantly managed by their GPs, having a
mean of ;140 visits per patient during
the study period (Table 3). These visits
were for the management of their co-
morbidities, shown in Tables 1 and 2,
as well as their T2D and OSA. Addition-
ally, patients in both groups had a mean
of 13–14 hospital outpatient visits per
patient (Table 3). However, there were
no statistically signiﬁcant differences
between the groups in their use of health
care resources over the study period.
CPAP-treated patients received signiﬁ-
cantly more prescriptions for respiratory
drugs (P , 0.02) and neurological drugs
(P , 0.03), and patients in the control
group received signiﬁcantly more pre-
scriptions for antidiabetes medication
(Table 3). Moreover, 7% of CPAP-treated
patients and 5% of control patients
started to use insulin amean 11.9months
and 4.6 months, respectively, after the
study start date. These patients contin-
ued to receive insulin prescriptions con-
tinuously for the rest of the study period.
Multiple regression showed the fol-
lowing over the 5 years:
1. The number of GP visits per patient
increased with higher comorbidity
scores (31.3 more visits for each
unit increase in CCIS at baseline [P ,
0.001]), number ofGP visits in the year
Table 1—Patients’ characteristics at baseline
CPAP-treated group Control group P
Patients (n) 150 150 ns
Age (years) 53.9 6 0.9 53.6 6 1.0 ns
Male (%) 82 83 ns
Body weight (kg) 114.0 6 1.9 109.5 6 2.0 ns
BMI (kg/m2) 38.9 6 0.6 35.4 6 0.5 ,0.001
Smokers (%) 51 68 ,0.02
CCIS (comorbidity index) 2.3 6 0.1 2.3 6 0.1 ns
Systolic blood pressure (mmHg) 137.5 6 1.7 140.3 6 1.7 ns
Diastolic blood pressure (mmHg) 82.0 6 1.0 84.3 6 1.1 ns
Patients with blood pressure .140/90 mmHg (%) 12 19 ns
Patients with blood pressure .140/#90 mmHg (%) 22 31 ns
Patients with blood pressure #140/.90 mmHg (%) 5 ,1 ns
HbA1c levels, % (mmol/mol) 7.5 6 2.4 (58.1 6 2.9) 7.4 6 2.4 (56.9 6 2.7) ns
GP visits in the year before the study start date 15.7 6 1.2 12.3 6 0.8 ns
Hospital admissions in the year before the study start date 0.2 6 0.1 0.1 6 0.1 ns
Patients diagnosed with speciﬁc symptoms in the year
before the study start date (%)
Obesity or morbid obesity 88 75 ,0.02
Hypertension 56 50 ns
Gastrointestinal disorder 37 37 ns
Respiratory disorder 37 25 ns
Breathless disorder 32 24 ns
Depression 23 24 ns
Cardiac arrhythmias 9 5 ns
Arthritis 8 10 ns
Angina 8 10 ns
Endocrine disorder 8 9 ns
Anxiety 4 2 ns
Ophthalmological disorder 3 3 ns
Gout 2 2 ns
Myocardial infarction 1 2 ns
Retinopathy 0 2 ns
Stroke 0 1 ns
Data are means 6 SE per patient unless otherwise indicated. ns, not signiﬁcant.
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before the study start date (2.3 more
visits for each GP visit in the year be-
fore the study start date [P, 0.001]),
and by sex (females had 31.9 more
visits than males [P , 0.01]).
2. The number of outpatient visits per
patient increased with the number
of hospital admissions in the year
before the study start date (6.6
more visits for each admission in
the year before the study start
date [P , 0.005]) and by sex (fe-
males had 5.6more visits thanmales
[P , 0.03]).
3. The number of hospital admissions
per patient increased with the num-
ber of hospital admissions in the year
before the study start date (0.8 more
admissions for each admission in the
year before the study start date [P,
0.01]).
Health Care Cost of Patient
Management
The 5-yearly NHS cost of managing pa-
tients in the CPAP-treated group was
£18,2346 1,033 per patient compared
with £14,0926 1,029 per patient in the
control group. Hence, the incremental
cost associated with CPAP treatment
was £4,141 6 1,588 per patient over
5 years (Table 4). GP visits were the
principal cost driver in both groups,
accounting for 41% and 54% of the
total NHS management cost of CPAP-
treated patients and control patients,
respectively.
Cost-effectiveness Analyses
Use of CPAP led to an increase in pa-
tients’ health status of 0.27 QALYs and
an increase in the total NHS cost of pa-
tientmanagement of £4,141. Hence, the
cost per QALY gained with CPAP was es-
timated to be £15,337 (i.e., 4,141 4
0.27).
Sensitivity Analyses
Bootstrapping demonstrated the distri-
bution in NHS costs and QALYs at 5 years
(Supplementary Fig. 1) from which it
was seen that, while there is some over-
lap in the costs of the twopatient cohorts,
the distribution of QALYs is distinct. A
cost-effectiveness acceptability curve
was generated from the bootstrapped
subsets (Supplementary Fig. 2), demon-
strating that at a cost-effectiveness
threshold of £20,000 per QALY, up to
87% of a cohort is expected to be cost-
effectively treated with CPAP compared
with no CPAP treatment.
Deterministic sensitivity analyses
were performed on all the model’s
Table 2—Patients’ outcomes over the study period
CPAP-treated group Control group P
Conditions with which patients were newly diagnosed (%)
Obesity or morbid obesity 0 6 ns
Depression 57 53 ns
Breathless disorder 40 40 ns
Hypertension 39 38 ns
Gastrointestinal disorder 49 50 ns
Ophthalmological disorder 47 42 ns
Cardiac arrhythmias 27 14 ,0.03
Respiratory disorder 30 43 ns
Arthritis 21 27 ns
Endocrine disorder 20 11 ns
Angina 16 21 ns
Anxiety 6 12 ns
Gout 11 7 ns
Stroke 4 6 ns
Retinopathy 2 11 ,0.02
Myocardial infarction 4 5 ns
BMI (kg/m2) 38.6 6 0.6 36.8 6 0.6 ns
Systolic blood pressure (mmHg)
Year 1 139.0 6 2.1 137.5 6 1.9 ns
Year 2 136.2 6 2.3 140.4 6 2.1 ns
Year 3 133.7 6 1.9 138.2 6 1.9 ns
Year 4 134.1 6 1.9 136.0 6 1.8 ns
Year 5 131.0 6 2.1 135.4 6 2.0 0.02
Diastolic blood pressure (mmHg)
Year 1 81.5 6 1.3 81.8 6 1.2 ns
Year 2 79.4 6 1.1 81.6 6 1.1 ns
Year 3 79.4 6 1.3 81.8 6 1.2 ns
Year 4 79.9 6 1.2 80.1 6 1.1 ns
Year 5 78.1 6 1.2 80.7 6 1.2 ,0.02
HbA1c, % (mmol/mol)
Year 1 7.5 6 2.6 (58.1 6 5.4) 7.9 6 2.6 (62.3 6 4.8) ns
Year 2 8.8 6 4.0 (72.6 6 19.7) 13.1 6 4.3 (119.7 6 23.5) ,0.05
Year 3 8.1 6 3.9 (65.4 6 18.8) 12.2 6 4.2 (109.9 6 22.5) ,0.05
Year 4 7.8 6 3.9 (61.6 6 18.7) 13.3 6 4.3 (121.9 6 23.8) ,0.03
Year 5 8.2 6 3.5 (66.0 6 15.0) 12.1 6 3.8 (108.4 6 17.9) ,0.03
QALYs 2.5 6 0.04 2.26 6 0.03 ,0.001
Data are means 6 SE per patient unless otherwise indicated. ns, not signiﬁcant.
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inputs, but only the main ﬁndings have
been presented (Supplementary Table
1). These analyses showed that for plau-
sible changes in the model’s inputs,
CPAP remains a cost-effective interven-
tion for OSA patients with T2D.
CONCLUSIONS
This comparative study aimed to deter-
mine the relative clinical outcomes and
cost-effectiveness of using CPAP to treat
OSA patients with T2D in clinical prac-
tice in the U.K. Accordingly, a random
sample of patients in the THIN database
who had a diagnosis of OSA and T2D and
were treated with CPAP was compared
with matched OSA and T2D patients
who were not treated with CPAP and
who had a clinical history for at least 5
years unless they died in order to ex-
clude patients who had moved or
changed their general practice. The ad-
vantage of using the THIN database
is that the patient pathways and associ-
ated resource use are basedon actual clin-
ical practice rather than trial protocol–
driven resource use. However, this natu-
ralistic approach does have its limitations.
Patients were not randomized to the
treatment they received. Hence, there
would have been differences between
the groups resulting in the hospital physi-
cian’s decision whether to offer CPAP and
the patient’s willingness to accept after
the diagnosis of OSA. Every attempt was
made to account for these differences and
to overcome the nonrandomized study
design. Differences in patients’ outcomes
and resource use between treatments
were adjusted for any heterogeneity in
age, sex, baseline comorbidities, baseline
blood pressure, baseline BMI, smoking
status, and number of GP visits and hospi-
tal admissions in the year before the study
start date. Moreover, 300 patients have
been included in the analysis, which
should have been a sufﬁciently large sam-
ple to allow for relevant baseline differen-
ces to be apparent. Nevertheless, there
will have been some differences that
havenot been accounted for. Additionally,
power calculations showed that the
Table 3—Mean health care resource use per patient over the study period
Resource CPAP-treated group
Control
group P
GP ofﬁce visits 138.4 6 6.9 140.5 6 6.7 ns
GP home visits 0.5 6 0.1 0.5 6 0.1 ns
Nurse visits 0.9 6 0.3 1.0 6 0.2 ns
Hospital outpatient visits 13.3 6 1.9 14.5 6 1.8 ns
Accident and emergency attendances 1.0 6 0.3 0.4 6 0.2 ns
Day case attendances 0.3 6 0.2 0.2 6 0.1 ns
Hospital admissions 1.3 6 0.2 0.8 6 0.2 ns
Surgical procedures 0.8 6 0.1 1.0 6 0.1 ns
Therapeutic procedures 0.8 6 0.1 0.4 6 0.1 ns
Laboratory tests 25.8 6 0.1 22.6 6 0.1 ns
Diagnostic tests 11.7 6 0.1 9.2 6 0.1 ns
Number of drug prescriptions
Analgesics 15.1 6 2.8 8.7 6 2.2 0.05
Antidiabetes drugs for T2D 16.8 6 4.0 27.1 6 3.7 ,0.02
Anti-infectives 7.7 6 1.0 4.1 6 0.9 ,0.01
Cardiovascular drugs 87.9 6 8.6 84.5 6 8.3 ns
Dermatological preparations 5.9 6 1.5 3.3 6 1.4 ns
Endocrine drugs 5.6 6 1.1 4.9 6 1.4 ns
Gastrointestinal drugs 15.1 6 2.1 10.6 6 2.2 ns
Genitourinary drugs 5.2 6 1.7 4.8 6 1.5 ns
Insulin 2.8 6 1.6 1.4 6 1.4 ns
Musculoskeletal drugs 9.9 6 1.9 8.9 6 2.1 ns
Neurological drugs 21.6 6 3.7 11.3 6 4.0 ,0.03
Ophthalmological drugs 4.1 6 1.1 0.7 6 1.2 ns
Otolaryngeal drugs 5.0 6 1.2 2.4 6 1.3 ns
Respiratory drugs 30.7 6 5.8 14.1 6 5.4 ,0.02
Wound care products 4.6 6 1.9 1.9 6 1.7 ns
Data are means 6 SE resource per patient unless otherwise indicated. ns, not signiﬁcant.
Figure 1—Patients’ mean (6SE bars) HbA1c levels over the study period.
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sample sizewas sufﬁciently large to detect
any signiﬁcant differences with 95%
power and a type I (a) error of 0.05 be-
tween the two groups, had they occurred,
as well as large enough to accurately as-
sess treatment patterns and health care
resource use attributable to managing
OSA and T2D in actual clinical practice.
For patients to be included in the data
set, they had to have received CPAP for
their OSA or be matched to these pa-
tients on the basis of their age, sex,
the same general practice, date of diag-
nosis of their OSA and T2D and not re-
ceived CPAP. Severity of OSA was not
included as a matching criteria, since
this was not documented in the pa-
tients’ records. All the patients in this
data set had their OSA diagnosed by a
respiratory physician. However, pa-
tients in both groups were subsequently
managed primarily by their GP, who saw
them on average every 2 weeks, but not
necessarily for OSA, and they only saw a
hospital physician about twice a year.
Moreover, it took a mean 20 months
to the start of CPAP treatment after a
diagnosis of OSA. The THIN data set in
this study covers the period from 2007
to 2011, so this is a reﬂection of how
most patients with OSA and T2D were
managed in the community in the U.K.
at that time. Nevertheless, this study
found that once started, compliance
with CPAP ranged from 93% in year 1
to 89% in year 5. This compliance rate
reﬂects “real-world” practice and is
much higher than those reported in
other studies (34). Our study does not
address the question of who should di-
agnose and manage OSA or how it
should be done or the more complex
question of integrated care pathways.
After adjustment for baseline differ-
ences, this study estimated that over
the ﬁrst 5 years after the study start
date, the incremental cost of initiating
CPAP treatment was a mean £4,141 and
leads to a 12% improvement in patients’
HRQoL (of 0.27QALYs), resulting ina cost
per QALY gain of £15,337. This value is
concordant with the cost-effectiveness
of using CPAP over 5 years, based on a
simulated modeled cohort of patients
with severe OSA (17). Additionally, use
of CPAP led to signiﬁcantly lower blood
pressure by year 5 and signiﬁcantly
lower HbA1c levels progressively over
the 5 years compared with untreated
patients. Regression analyses found
that there was no relationship between
the number of antidiabetes medication
prescriptions and HbA1c levels. These
observations reinforce the ﬁndings of
others that use of CPAP can reduce hy-
pertension (35) and possibly reduce in-
sulin resistance (18–20), leading to
lower serum glucose levels and HbA1c
levels (21,22,36). However, this is the
ﬁrst time a study, based on the manage-
ment of patients in actual clinical prac-
tice, has shown that use of CPAP leads to
lower HbA1c levels over ﬁve consecutive
years compared with untreated pa-
tients. This difference was due to the
HbA1c levels having only increased by
0.7% over 5 years among CPAP-treated
patients compared with 4.7% over the
same period in the untreated patients.
As HbA1c is a surrogate measure of gly-
cemic control, this study’s ﬁndings sup-
port the notion that in someway the use
of CPAP facilitates glycemic control in
OSA patients with T2D. Moreover, the
untreated patients required signiﬁ-
cantly more prescriptions for antidiabe-
tes drugs. Hence, it could be postulated
that CPAP treatment reduces insulin re-
sistance in these patients. Conversely, it
may just be that those who accept CPAP
also comply better with their medica-
tion. Also, CPAP-treated patients may
be less sleepy and more inclined to
look after their diabetes better. Clearly,
these observations warrant further
investigation.
A reduction in HbA1c level has been
shown to be associated with a reduction
in the risk of macrovascular and micro-
vascular complications associated with
T2D (7,37). This is consistent with the
ﬁndings from this study, since the rela-
tive risks of developing angina, myocar-
dial infarction, stroke, and diabetic
retinopathy are all reduced in the
CPAP-treated group (Table 2). More-
over, the increased rate of diabetic ret-
inopathy in the untreated control
patients is compatible with the ﬁndings
of others (38).
This study found that signiﬁcantly
more CPAP-treated than control pa-
tients had a diagnosis of cardiac arrhyth-
mias. This is difﬁcult to explain, since
use of CPAP has been shown to reduce
cardiac arrhythmias (39). We have at-
tempted to account for any differences
between the groups, but severity of
some patients’ symptoms remains un-
known, as not all of this information
was recorded in their records. Hence,
the CPAP-treated patients may have
had more severe OSA than the control
patients, which we have not been able
to address. Notwithstanding this, the
CPAP-treated patients had better glyce-
mic control of their diabetes over 5 years
and there were no signiﬁcant differen-
ces in baseline symptoms between
the groups. Nevertheless, regression
analyses found no relationship between
CPAP adherence and the study’s out-
comes, but this may reﬂect the fact
that adherence data were only available
for 11 patients.
This study has a number of other lim-
itations. The results were censored at
5 years and excluded the costs and
Table 4—Mean 5-yearly NHS cost (at 2011/2012 prices) of resource use per patient
Resource
CPAP-treated
group Control group
Incremental cost
associated with
CPAP treatment
GP visits 7,428.33 (41) 7,541.04 (54) 2112.71 (23)
Hospitalization 2,466.04 (14) 1,517.56 (11) 948.48 (23)
Prescribed drugs 3,714.65 (20) 2,140.47 (15) 1,574.19 (38)
CPAP 1,696.00 (9) 0.00 (0) 1,696.00 (41)
Outpatient visits 1,786.51 (10) 1,947.70 (14) 2161.19 (24)
Tests and procedures 518.06 (3) 402.55 (3) 115.52 (3)
Diagnosis of OSA 343.14 (2) 343.14 (2) 0.00 (0)
Day case attendances 51.30 (,1) 34.20 (,1) 17.10 (,1)
Nurse visits 53.77 (,1) 59.75 (,1) 25.97 (,21)
Accident and emergency
attendances 116.12 (1) 46.45 (,1) 69.67 (2)
Community care 59.56 (,1) 59.56 (,1) 0.00 (0)
Total 18,233.50 (100) 14,092.42 (100) 4,141.08 (100)
Data are mean cost (£) of resource per patient (% of total cost).
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consequences of managing patients be-
yond this period. The THIN database
may have underrecorded use of some
health care resources outside the GP’s
surgery, such as some home visits made
by clinicians, outpatient visits, atten-
dance at accident and emergency de-
partments, and hospital admissions if
not documented in the GP records.
The analysis excluded hospital-based
prescribing, but this should have mini-
mal impact on the results, since most
prescribing is undertaken by GPs in the
community.
The analysis only considered the cost
of NHS resource use for the “average
patient,” and no attempt was made to
stratify resource use and costs according
to sex, comorbidities, suitability of pa-
tients for different treatments, and
other disease-related factors. Also ex-
cluded were the costs incurred by pa-
tients and indirect costs incurred by
society as a result of patients taking
time off work.
This evaluation provided an estimate
of the clinical outcomes, resource impli-
cations, and associated costs attribut-
able to managing OSA patients with
T2D.While the study results are compel-
ling, the analyses of clinical outcomes
were based on clinicians’ entries into
their patients’ records and inevitably
subject to a certain amount of impreci-
sion and lack of detail. Moreover, the
computerized information in the THIN
database is collected by GPs for clinical
care purposes and not for research. Pre-
scriptions issued by GPs and practice
nurses are recorded in the database,
but it does not specify whether the pre-
scriptions were dispensed or patient
compliance with the product. Conse-
quently, this study’s ﬁndings should
provide a framework for a randomized
controlled trial comparing the use
of CPAP in the management of OSA
patients with T2D to prospectively
measure a range of clinical outcomes
and HRQoL in combination with cost-
effectiveness metrics. However, as
discussed earlier, this will be almost
impossible if patients with OSA-related
symptoms are considered for recruit-
ment, as most physicians and patients
would not be prepared to wait 5 years
for treatment with CPAP after allocation
to a control arm.
In conclusion, within the limitations
of the data set, ﬁrst-line CPAP treatment
in OSA patients with T2D leads to signif-
icantly lower blood pressure and signif-
icantly better controlled diabetes and
affords a cost-effective use of NHS re-
sources. This study also demonstrates
that use of CPAP can potentially facili-
tate glycemic control in OSA patients
with T2D over the longer term. This ob-
servation has the potential to alter
treatment decisions, particularly if con-
ﬁrmed in a prospective trial.
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